Findings

What do systematic reviews say?

1,679 questions · 1,720 findings · 335 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 192 · 11.2%GRADE not reported 75 · 4.4%Very low 526 · 30.6%Low 504 · 29.3%Moderate 305 · 17.7%High 118 · 6.9%

Summary of findings table ‐ Systemic therapy vs control

Health‐related quality of life (HRQoL) · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 208 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Safety of systemic therapies for the treatment of AIMSS · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1250 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Change in pain from baseline to end of intervention · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1099 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Change in stiffness from baseline to end of intervention · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 295 participants
Very low

Intervention not reported

Cognitive function using validated neuropsychological tests · patients with a primary brain tumour, within two weeks of surgical intervention

1 finding from 1 review

Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 53 participants
Very low

Hydrocortisone vs placebo

Severity of PTSD symptoms · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propranolol vs placebo

Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

Severity of PTSD symptoms ‐ Clinician‐rated · adults (aged 18 and older) exposed to a traumatic event

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Very low

Gabapentin vs placebo

Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

PTSD rate at 3 months · adults (aged 18 and older) exposed to a traumatic event

It is very uncertain whether gabapentin changes PTSD rate at 3 months compared with placebo (very low certainty).

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.8 [0.18, 3.59]
1 study · 26 participants
Very low

Gabapentin vs placebo

Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

PTSD rate at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propranolol vs placebo

Severity of PTSD symptoms ‐ Clinician‐rated · adults (aged 18 and older) exposed to a traumatic event

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 86 participants
Very low

Propranolol vs placebo

Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propranolol vs placebo

PTSD rate at 3 months · adults (aged 18 and older) exposed to a traumatic event

It is very uncertain whether propranolol changes PTSD rate at 3 months compared with placebo (very low certainty).

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.77 [0.31, 1.92]
3 studies · 88 participants
Very low

Propranolol vs placebo

Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found